Bio Rad Laboratories Inc reports results for the quarter ended March 31 - Earnings Summary

Bio-Rad Laboratories

02/05/2025 06:00

Bio Rad Laboratories Inc BIO.N reported quarterly adjusted earnings of $2.54​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $2.29.  The mean expectation of seven analysts for the quarter was for earnings of $1.81 per share. Wall Street expected results to range from $1.47  to $1.96 per share.

Revenue fell 4.2% to $585.40 million from a year ago; analysts expected $573.26 million.

The company reported quarterly net income of $64 million.

Bio Rad Laboratories Inc shares had risen by 0.2% this quarter and lost 25.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 31.9% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Bio Rad Laboratories Inc is $367.50

This summary was machine generated from LSEG data May 2 at 04:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
1.81
2.54
Beat
Dec. 31 2024
2.87
2.90
Beat
Sep. 30 2024
1.16
2.01
Beat
Jun. 30 2024
2.01
3.11
Beat